You will not be allowed to compare more than 4 products at a time
View compare
Building the Future of Low-Cost, Reproducible Life-Science Reagents
Atheris Bio develops chemically defined, serum-free, and animal-component-free media and reagent platforms for research, diagnostics, vaccine development, and therapeutic manufacturing.
Our focus: reduce variability, improve reproducibility, and lower cost at the foundation of biological workflows.
The Problem: Variable Reagents LimitScientific Progress
Across academic laboratories,
vaccine programs, and gene therapy pipelines, foundational biological reagents
remain:
● Serum- and protein-dependent
● Poorly defined at the molecular level
● Subject to lot-to-lot variability
● Expensive at scale
● Difficult to translate into regulated workflows
Industry Challenges
● Serum-based media introduce performance variability
● Undefined components complicate reproducibility
● High reagent costs restrict experimental scale
● Animal-derived inputs create regulatory friction
● Inconsistent workflows slow therapeutic translation
Investor Insight:
When foundational inputs are inconsistent, downstream outcomes become unpredictable.
The Atheris Bio Solution: Chemically Defined, Animal-Free Platforms
Atheris Bio replaces serum- and protein dependent systems with chemically defined, reproducible reagent platforms engineered for:
● Reliable experimental outcomes
● Reduced lot-to-lot variability
● Scalable cost structure
●Simplified regulatory alignment
●Transition from research to early manufacturing
Our formulations are built around controlled chemical composition, enabling measurable performance across workflows.
Focus Platforms
Serum-Free Mycobacterial Media
Defined broth systems for TB, BCG, and NTM research, diagnostics, and vaccine development. Designed to reduce clumping, improve quantification accuracy, and remove animal-derived variability.
Protein-Free HEK293 Media
Chemically defined systems for viral vector research and gene therapy development, supporting consistent transfection and reproducible performance.
Defined Reagent Platforms (Buffer &
Handling Systems)
Modular, scalable buffer systems engineered for:
● Cell washing
● Handling and transport
● Media transition workflows
● Process development support
Regulatory & Quality Orientation
Atheris Bio products are designed with documentation discipline from the outset:
● Defined formulation specifications
● COA-based quality controls
● Endotoxin specification targets
● Lot traceability systems
● Manufacturing SOP architecture
Early integration of quality systems supports future regulatory alignment.
Team & Execution
Atheris Bio is built by scientists focused on:
● Defined reagent formulation
● Viral vector and microbial workflows
● Translational research environments
● Reproducibility-driven product design
Execution emphasis:
Scientific rigor. Controlled formulation. Practical usability.
Investment Opportunity
As research, vaccine, and gene therapy pipelines demand higher reproducibility and lower cost, defined reagent infrastructure becomes foundational.
Atheris Bio is developing scalable, chemically defined platforms positioned to support this transition.
Traction & Development Roadmap
Current Progress
● Platform R&D validation in progress
● Early-stage customer discovery across research and biotech
● Defined product portfolio architecture
● Scalable SKU and QC documentation framework
Next Milestones
● Research-use product launches
● Beta user validation programs
● Strategic distributor discussions
● Expansion into therapeutic-adjacent workflows